Tetraphase (TTPH) PT Raised to $15 as Phase 3 Trial Ready
Tweet Send to a Friend
Needham & Company analyst Alan Carr reiterated a Buy rating and raised his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE